Sökning: "Myeloablative conditioning"
Visar resultat 1 - 5 av 18 avhandlingar innehållade orden Myeloablative conditioning.
1. Health-related quality of life after stem cell transplantation - The firs year
Sammanfattning : Health-related quality of life after stem cell transplantation – The first year Inger Andersson Institute of Health and Care Sciences at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden Abstract High-Dose Chemotherapy (HDC) followed by Stem Cell Transplantation (SCT) has been proven to be beneficial for a variety of haematological diseases, solid tumours and immune disorders. Despite improved care and treatment, SCT continues to produce significant long-term complications with impaired functioning and distressing symptoms. LÄS MER
2. Cyclophosphamide and treosulfan in the conditioning regimen prior to allogeneic stem cell transplantation
Sammanfattning : Allogeneic stem cell transplantation (SCT) is a curative treatment for malignant and non-malignant diseases. However, transplantation related morbidity and mortality are major drawbacks affecting the survival and life quality of the patients. LÄS MER
3. Pathophysiological aspects of transplantation-related complications following busulphan/cyclophosphamide conditioning regimen in mouse model
Sammanfattning : Hematopoietic stem cell transplantation (HSCT) is a curative treatment for several malignant and non-malignant disorders. However, transplantation related morbidity and mortality limit its use. The complications of the HSCT procedure can be caused by several factors including toxicity of the conditioning regimen and allogeneicity. LÄS MER
4. Conditioning associated effects on oral mucosa and salivary function in allogeneic stem cell recipients
Sammanfattning : Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for patients with a range of disorders of the immunohematopoietic system. In HSCT recipients, acute complications in the oral cavity are common. LÄS MER
5. Immune reconstitution after allogeneic hematopoietic stem cell transplantation
Sammanfattning : After treatment with allogeneic hernatopoietic stem cell transplantation (HSCT) the patient suffers from a deficient immune system for at least 12 months or longer. During this period, the patient is susceptible to infections and if the state of immune deficiency is prolonged there is an increased risk of relapse of the underlying malignancy as well as development of secondary malignancies. LÄS MER